Volume 11, Number 8—August 2005
Research
Pseudomonas aeruginosa, Staphylococcus aureus, and Fluoroquinolone Use
Table 3
Longitudinal GEE models*
Drug | FQ-R P. aeruginosa |
MRSA |
||
---|---|---|---|---|
Coefficient | p value | Coefficient | p value | |
Total FQ | ||||
Previous year's resistance | 0.875 | <0.001 | 0.804 | <0.001 |
Total FQ use | 0.002 | 0.883 | 0.025 | 0.155 |
Time | -0.312 | 0.554 | 1.04 | 0.040 |
Constant | 6.75 | 0.001 | 4.61 | 0.058 |
Levofloxacin | ||||
Previous year's resistance | 0.868 | <0.001 | 0.818 | <0.001 |
Levofloxacin use | 0.005 | 0.548 | 0.012 | 0.033 |
Time | -0.317 | 0.579 | 1.04 | 0.041 |
Constant | 6.78 | 0.001 | 6.38 | 0.001 |
Ciprofloxacin | ||||
Previous year's resistance | 0.866 | <0.001 | 0.845 | <0.001 |
Ciprofloxacin use | -0.018 | 0.226 | -0.004 | 0.848 |
Time | -0.393 | 0.475 | 0.991 | 0.079 |
Constant | 8.185 | <0.001 | 6.55 | 0.033 |
*Association of fluoroquinolone and pathogen resistance over time controlling for prior year resistance. GEE, generalized estimating equations; FQ-R P. aeruginosa, fluoroquinolone-resistant Pseudomonas aeruginosa; MRSA, methicillin-resistant Staphylococcus aureus.